TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06431971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talineuren
Description: Talineuren infusion weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion weekly
Study: NCT05382767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKDB-501A
Description: Muscle Spasticity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox®
Description: Muscle Spasticity
Study: NCT05157802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity coaching
Description: Physical activity coaching over 5 sessions
Study: NCT06055738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: 240mg,d1,iv,Q21D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound Paclitaxel
Description: 260mg/m2,d1,iv,Q21D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2,d1,iv,Q21D
Study: NCT05414357

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging at rest and in activation with attentional task
Description: Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:~* Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2).~* Biological and physiological measurements~* Spatial memory task~* Cognitive battery~* Questionnaires (sleep, quality of life)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging at rest and in activation with attentional task
Description: Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:~* Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2).~* Biological and physiological measurements~* Spatial memory task~* Cognitive battery~* Questionnaires (sleep, quality of life)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging at rest and in activation with attentional task
Description: Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:~* Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2).~* Biological and physiological measurements~* Spatial memory task~* Cognitive battery~* Questionnaires (sleep, quality of life)
Study: NCT04903743

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: group B received 28ml of 0.25% bupivacaine and 2ml normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: group B received 28ml of 0.25% bupivacaine and 2ml normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate
Description: group BM received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
Study: NCT05397782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioNourish, a component of Flourish HEC
Description: BioNourish, one of three parts of the Flourish HEC system, is a vaginal moisturizing gel - a Class II medical device with FDA 510k clearance obtained in 2020.
Study: NCT04832100

Intervention type: DRUG
Intervention: Pregabalin 150mg, imipramine 25mg
Description: Conventional treatment for fibromyalgia was given to patients. Clinical follow-ups with questionnaires and interview were arranged then.
Study: NCT05370703

Intervention type: BEHAVIORAL
Intervention: My A:care
Description: Mobile application with Motivational messages

Intervention type: BEHAVIORAL
Intervention: Smart Coach
Description: Mobile application with Motivational messages
Study: NCT04672382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: During the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm) located 3 cm apart. Two areas will be treated with an intradermal injection of morphine (0.05 ml, 0.1 mg/ml), and two areas with an intradermal injection of isotonic saline.
Study: NCT05771883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM0306
Description: IMM0306 is a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα. The Fc segment of the recombinant protein in IMM0306 is IgG1 and has been modified by ADCC-enhanced genetic engineering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide capsule
Description: Chemical name 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidin-2,6-dione, molecular formula C 13H 13 N 3 O 3, is an anti-tumor drug developed by Celgene Biopharmaceutical Company in the United States, with multiple effects such as anti-tumor, immunomodulatory and anti-angiogenesis
Study: NCT03972891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention break of 12 weeks
Description: The intervention of this study is a break of the intervention for 12 weeks under the following conditions:~* no therapeutic intervention during the break~* no language-specific specific exercises~* language-specific strategies in everyday life can be applied, e.g. modeling techniques
Study: NCT05536388

Intervention type: OTHER
Intervention: Biological Sample Collection
Description: Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)

Intervention type: OTHER
Intervention: Biological Sample Collection
Description: Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)

Intervention type: OTHER
Intervention: Biological Sample Collection
Description: Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)
Study: NCT06434987

Intervention type: PROCEDURE
Intervention: Retrograde Inferior Vena Cava Perfusion
Description: Retrograde inferior vena cava (RIVP) involves perfusing oxygenated blood into the inferior vena cava, which then flows towards the viscera, abdominal organs and lower extremities. By maintaining perfusion to these regions during cardiopulmonary bypass (CPB) and induced hypothermia, Retrograde inferior vena cava (RIVP) helps mitigate the risk of ischemic injury to the abdominal organs. Following the initiation of total cardiopulmonary bypass, the body temperature will be gradually lowered to achieve deep-moderate hypothermia ( 24-38°C). This procedure will involve the combination of selective antegrade cerebral perfusion and retrograde inferior vena cava perfusion. Antegrade perfusion will be maintained at a flow rate of 5-7mL/min/kg, while retrograde perfusion will be regulated to sustain the required pumm pressure and blood flow.

Intervention type: PROCEDURE
Intervention: Antegrade cerebral perfusion
Description: After mild to moderate hypothermia is achieved, a cannula will be inserted into the right axillary artery, brachiocephalic or innominate artery to provide continuous flow to the brain. A flow rate of 5-7mL/min/kg will be maintained.
Study: NCT04646564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
Study: NCT04760145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent Exercise with Blood Flow Restriction
Description: * 10 minutes of initial warm-up.~* 20 minutes of strength exercises.~* 10 minutes of resistance exercises.~* 10 minutes of coordination and balance exercises.~* 5 minutes of flexibility.~* 5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed with blood flow restriction.
Study: NCT04646564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care
Description: patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy + standard of care
Description: Patients receive radiotherapy to all known metastases. SBRT technique is preferred, especially for metastases in bone, lung and liver. Conventional RT can be used when SBRT is not appropriate, such as metastasis in mediastinal or contralateral supraclavicular nodal regions. Total doses of 30Gy to 50Gy in 5 fractions for SBRT are recommended depending on the tolerance of adjacent normal tissue. Total dose of 60Gy in 25 fractions is recommended for conventional RT.~Patients can receive systemic therapy concurrently with RT at the discretion of treating radiation oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist.
Study: NCT04455932

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abbreviated non-contrast MRI of the liver
Description: every 6 months

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound surveillance
Description: every 6 months

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiphase contrast-enhanced liver MRI
Description: screening
Study: NCT06150118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT+VR (Cognitive behavioral therapy and virtual reality)
Description: The investigators are testing whether this intervention protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR (Virtual reality)
Description: The investigators are testing whether this intervention protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT (Cognitive behavioral therapy)
Description: The investigators are testing whether this intervention protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The investigators are testing whether the placebo control protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
Study: NCT06225908

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus posterior superior intercostal plane block
Description: application of local anestesic under serratus posterior superior muscle at the level of second costa
Study: NCT04760145

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent Exercise without Blood Flow Restriction
Description: * 10 minutes of initial warm-up.~* 20 minutes of strength exercises.~* 10 minutes of resistance exercises.~* 10 minutes of coordination and balance exercises.~* 5 minutes of flexibility.~* 5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed without blood flow restriction.
Study: NCT06198725

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trimtab
Description: High fiber group will take Trimtab (a kind of multi bran and high fiber grain compound powder) 60g per day to intake 28g dietary fiber for 12 weeks.
Study: NCT05654077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T Cell Injection
Description: intravenously once, and the dose group was 3.0 × 10\^6cells/kg、9.0 × 10\^6cells/kg、1.5 × 10\^7cells/kg。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
Study: NCT05074108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot study
Description: Aiming for an interaction 6 week course that will discuss many aspects of health and wellness.
Study: NCT05667077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: The amantadine group is treated with amantadine capsules 100mg twice a day for two weeks
Study: NCT04671732

Intervention type: PROCEDURE
Intervention: Fenestrated endovascular aortic aneurysm repair
Description: Fenestrated endovascular aortic aneurysm repair consists in excluding a juxtrenal or suprarenal aneurysm by deploying a covered stent (stent graft) in the aorta so as to created sealing zones on both sides of the aneurysm. Since the proximal sealing is located in the visceral segment of the aorta, fenestrations are created to maintain blod flow in renal and visceral arteries. These fenestrations are custom made for each patient. Brindging covered stents are deployed between each fenestration and corresponding target arteries in order to insure sealing of the system.

Intervention type: PROCEDURE
Intervention: open repair of abdominal aortic aneurysm.
Description: Open repair of abdominal aortic aneurysms consists in cross-clamping the aorta on both sides of the aneurysm and replace the diseased segment by a prosthetic graft.
Study: NCT04866745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetotherapy plus exercise
Description: The VARIMAG-4E magnetotherapy device will be used. It is a pulsed radiofrequency energy device. The device has a voltage of 220V, 4 amps of intensity, 50 Hz of frequency and a maximum power of 100 Gauss. For the active treatment application, the patient will be in supine position and will introduce both knees in the 50 cm coil in case of bilateral knee osteoarthritis. In the case of unilateral knee osteoarthritis, the affected knee will be introduced in the 30cm coil. The duration of the treatment will be 20 minutes, the frequency administered will be 50 Hz and a power of 100 Gauss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave plus exercise
Description: The application of deep heating therapy will be with the patient in a sitting position. The VARITRON 250-EP microwave device will be used with a frequency of 2450 MHz and a maximum output power of 250W. In the case of unilateral knee osteoarthritis, the circular applicator with a diameter of 170mm will be placed approximately 15 cm from the knee. The duration of the session will be 20 minutes, 10 minutes over the internal face and 10 minutes over the external face of the knee. In the case of bilateral knee osteoarthritis, the large lumbar applicator will be placed approximately 15 cm from the anterosuperior face of both knees for 20 minutes. The patient will have to perceive a moderate heat sensation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Magnetotherapy plus exercise
Description: The protocol and device will be the same in the active/placebo treatment. The sham device does not emit an electromagnetic field. The energy from the active device is not felt by the user, and the active device cannot be distinguished in any way from the placebo device.
Study: NCT06206096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin+capecitabine+bevacizumab+PD-1 antibody
Description: oxaliplatin will be administered once every 3 weeks at a dose of 130 mg/m2; Capecitabine will be taken orally at a dose of 1g/m2 twice daily for continuous oral administration over 14 days; Bevacizumab will be administered intravenously every 3 weeks at a dose of 7.5 mg/kg; PD-1 antibody was given due to different types.
Study: NCT05027386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib, Irinotecan, Temozolomide
Description: The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.
Study: NCT05676918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention
Description: PPI includes 2 modules: hedonic well-being and eudaimonic well-being.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: CBT includes 3 modules: behavioral activation, cognitive restructuring, and interpersonal skills.
Study: NCT05330026

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragm´s study during yoga breathing
Description: Study and compare the activation of the diaphragm during different breaths: rest, ujjayi and pursed lips

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Diaphragm´s study during yoga breathing
Description: Study and compare the activation of the diaphragm during different breaths: rest, ujjayi and pursed lips
Study: NCT05589792

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo before sleep for 3 nights before the study (inclusive)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide 250 mg 3 nights before the study at bedtime, Acetazolamide 500 mg for 2 nights before the study (inclusive) at bedtime.
Study: NCT06123013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Assisted Relation Intervention (MARI)
Description: A standardized 30-minute MARI intervention, personalized to the participant's music and imagery preferences. During the MARI intervention, the board certified music therapist (MT-BC) will provide live guitar accompaniment personalized to the participant's music preferences and read from a standardized script directing the participant to relax muscles of the body, practice deep breaths, and explore a relaxing place.
Study: NCT05874206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cratos™ Stent Graft
Description: Cratos™ Stent Graft TEVAR procedure for the treatment of aortic lesions.
Study: NCT05977907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an investigational drug in this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IO102-103
Description: IO102-103 is an investigational drug in this study.
Study: NCT05299983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyMenoPlan
Description: Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants are asked to spend at least 20 minutes on at least one of the following websites:~1. North American Menopause Society: https://www.menopause.org/for-women~2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause
Study: NCT05056428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness program
Description: The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
Study: NCT04549402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy group
Description: The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video group
Description: The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
Study: NCT06253416

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: a home exercise program consist of stretching and strengthening exercises , 5 repetitions of each exercise three days a week for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: exercise freely and without supervision with their daily routine
Study: NCT05315609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Meditation
Description: This 4-week VR program will use the Oculus Pro-Quest 2 headsets for the 15-minute seated VR meditation twice per week for a total of 8 sessions over the 4 weeks.
Study: NCT05198713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New hearing aid
Description: Participants will complete testing while using a novel hearing aid which has been fit to compensate for their hearing loss.
Study: NCT05623891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-B5-IgG4
Description: 177Lu-B5-IgG4 injection followed by SPECT scan